Title: EGFR participates downstream of ERα in estradiol-17β-D-glucuronide-induced impairment of Abcc2 function in isolated rat hepatocyte couplets.
Journal: Archives of toxicology 20160401
Title: Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Journal: International journal of oncology 20120801
Title: Irreversible protein kinase inhibitors: balancing the benefits and risks.
Journal: Journal of medicinal chemistry 20120726
Title: 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120301
Title: Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Journal: Lung cancer (Amsterdam, Netherlands) 20110801
Title: Epidermal growth factor treatment switches δ-opioid receptor-stimulated extracellular signal-regulated kinases 1 and 2 signaling from an epidermal growth factor to an insulin-like growth factor-1 receptor-dependent mechanism.
Journal: Molecular pharmacology 20110201
Title: Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Journal: Cancer research 20071101
Title: Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Journal: Cancer research 20061201
Title: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Journal: The Journal of clinical investigation 20061002
Title: Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Journal: Journal of medicinal chemistry 20060223
Title: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Journal: PLoS medicine 20051101
Title: An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
Journal: Cancer research 20050815
Title: EGFR pharmacogenomics: the story continues to mutate and evolve.
Journal: American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101
Title: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
Journal: Molecular pharmacology 20040601
Title: 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
Journal: Journal of medicinal chemistry 20010816
Title: Discafani CM, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N--[(3-bromophenyl)amino-6-quinazolinyl-2-butynamide (CL-387,785). Biochem Pharmacol. 1999 Apr 15;57(8):917-25.
Title: Sweeney WE, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000 Jan;57(1):33-40.
Title: Greulich H, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313.
Title: Kobayashi S, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15;65(16):7096-101.
